354 related articles for article (PubMed ID: 11374409)
1. Outcome of kidney transplants in patients known to be flow cytometry crossmatch positive.
Scornik JC; Clapp W; Patton PR; Van der Werf WJ; Hemming AW; Reed AI; Howard RJ
Transplantation; 2001 Apr; 71(8):1098-102. PubMed ID: 11374409
[TBL] [Abstract][Full Text] [Related]
2. Living-donor kidney transplant in T-cell and B-cell flow cytometry crossmatch-positive patients.
Terasaka S; Kitada H; Okabe Y; Kawanami S; Noguchi H; Miyamoto K; Tsuchimoto A; Masutani K; Tanaka M
Exp Clin Transplant; 2014 Jun; 12(3):227-32. PubMed ID: 24907723
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic flow cytometric crossmatch in renal transplantation: a single assay to simultaneously detect antibody binding and cytotoxicity.
Thammanichanond D; Athimang W; Paisooksantivatana K; Mongkolsuk T; Ingsathit A; Worawichawong S; Kitpoka P; Jirasiritham S; Kantachuvesiri S
Transplant Proc; 2012 Jan; 44(1):62-5. PubMed ID: 22310580
[TBL] [Abstract][Full Text] [Related]
4. Specificity of preformed alloantibodies causing B cell positive flow crossmatch in renal transplantation.
Lobashevsky AL; Senkbeil RW; Shoaf J; Mink C; Rowe C; Lobashevsky ES; Burke R; Hudson S; Deierhoi MH; Thomas JM
Clin Transplant; 2000 Dec; 14(6):533-42. PubMed ID: 11127305
[TBL] [Abstract][Full Text] [Related]
5. Weak humoral posttransplant alloresponse after a well-HLA-matched cadaveric kidney transplantation.
Matinlauri IH; Kyllönen LE; Eklund BH; Koskimies SA; Salmela KT
Transplantation; 2004 Jul; 78(2):198-204. PubMed ID: 15280678
[TBL] [Abstract][Full Text] [Related]
6. Donor-specific antibodies after transplantation by flow cytometry: relative change in fluorescence ratio most sensitive risk factor for graft survival.
Christiaans MH; Overhof-de Roos R; Nieman F; van Hooff JP; van den Berg-Loonen EM
Transplantation; 1998 Feb; 65(3):427-33. PubMed ID: 9484765
[TBL] [Abstract][Full Text] [Related]
7. The use of positive B cell flow cytometry crossmatch in predicting rejection among renal transplant recipients.
Kotb M; Russell WC; Hathaway DK; Gaber LW; Gaber AO
Clin Transplant; 1999 Feb; 13(1 Pt 2):83-9. PubMed ID: 10081642
[TBL] [Abstract][Full Text] [Related]
8. Luminex Solid-Phase Crossmatch for De Novo Donor-Specific Antibodies in Living-Donor Related Transplants.
Mehrotra S; Sharma RK; Mayya M; Gupta A; Prasad N; Kaul A; Bhadauria DS
Exp Clin Transplant; 2017 Aug; 15(4):394-399. PubMed ID: 28447925
[TBL] [Abstract][Full Text] [Related]
9. Significance of a T-lymphocytotoxic crossmatch in liver and combined liver-kidney transplantation.
Neumann UP; Lang M; Moldenhauer A; Langrehr JM; Glanemann M; Kahl A; Frei U; Bechstein WO; Neuhaus P
Transplantation; 2001 Apr; 71(8):1163-8. PubMed ID: 11374419
[TBL] [Abstract][Full Text] [Related]
10. The acceptable reactive crossmatch (ARC), post-transplant monitoring, and their impact on kidney transplantation: a single center experience.
Leone JP; Bowers V; Baliga R; Sanders C; LeFor W; Becker D; Thompson D; Resto-Ruiz S; Lopez-Cepero M
Clin Transpl; 2011; ():373-9. PubMed ID: 22755434
[TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation.
Caro-Oleas JL; González-Escribano MF; González-Roncero FM; Acevedo-Calado MJ; Cabello-Chaves V; Gentil-Govantes MÁ; Núñez-Roldán A
Nephrol Dial Transplant; 2012 Mar; 27(3):1231-8. PubMed ID: 21810767
[TBL] [Abstract][Full Text] [Related]
12. Living related donor kidney transplantation in patients with a positive flow cytometry crossmatch.
Hong JH; Sadeghian M; Sumrani N; Distant DA; Sommer BG; Norin AJ
Transplant Proc; 1996 Jun; 28(3):1614-5. PubMed ID: 8658808
[No Abstract] [Full Text] [Related]
13. Intravenous immunoglobulin and thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell crossmatch-positive patients.
Akalin E; Ames S; Sehgal V; Fotino M; Daly L; Murphy B; Bromberg JS
Transplantation; 2003 Nov; 76(10):1444-7. PubMed ID: 14657683
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of low levels of preformed alloantibodies detected by flow cytometry in the first year post-kidney transplantation.
Michelon T; Schroeder R; Fagundes I; Canabarro R; Sporleder H; Rodrigues H; Silveira J; Montagner J; Garcia V; Neumann J; Graudenz M
Transplant Proc; 2005; 37(6):2750-2. PubMed ID: 16182800
[TBL] [Abstract][Full Text] [Related]
15. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
Lee PC; Ozawa M
Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
[TBL] [Abstract][Full Text] [Related]
16. Hidden perils in a highly sensitized kidney transplant recipient.
Ford S; Summers S; Cantwell L; Mulley W
Nephrology (Carlton); 2012 Apr; 17 Suppl 1():9-11. PubMed ID: 22497647
[TBL] [Abstract][Full Text] [Related]
17. IgG donor-specific crossmatches are not associated with graft rejection or poor graft survival after liver transplantation. An assessment by cytotoxicity and flow cytometry.
Donaldson PT; Thomson LJ; Heads A; Underhill JA; Vaughan RW; Rolando N; Williams R
Transplantation; 1995 Nov; 60(9):1016-23. PubMed ID: 7491675
[TBL] [Abstract][Full Text] [Related]
18. Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts.
Lawrence C; Willicombe M; Brookes PA; Santos-Nunez E; Bajaj R; Cook T; Roufosse C; Taube D; Warrens AN
Transplantation; 2013 Jan; 95(2):341-6. PubMed ID: 23197178
[TBL] [Abstract][Full Text] [Related]
19. Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation.
Gloor JM; DeGoey S; Ploeger N; Gebel H; Bray R; Moore SB; Dean PG; Stegall MD
Transplantation; 2004 Jul; 78(2):221-7. PubMed ID: 15280682
[TBL] [Abstract][Full Text] [Related]
20. Flow cytometric crossmatching and outcome one year after renal transplantation.
Talbot D; Shenton BK; Givan AL; Cavanagh G; Proud G; Taylor RM
Transpl Int; 1992; 5 Suppl 1():S604-5. PubMed ID: 14621887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
